Mainz Biomed NV (FRA:4TO) Change In Payables And Accrued Expense : €-0.42 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Change In Payables And Accrued Expense?

Mainz Biomed NV's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Mainz Biomed NV's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Mainz Biomed NV's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €0.08 Mil. It means Mainz Biomed NV's Accounts Payable & Accrued Expense increased by €0.08 Mil from Dec. 2023 to Dec. 2024 .

Mainz Biomed NV Change In Payables And Accrued Expense Historical Data

The historical data trend for Mainz Biomed NV's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Change In Payables And Accrued Expense Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.13

0.58

1.56

0.66

0.08

Mainz Biomed NV Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial									1.43	-0.87	0.45	-	-

Mainz Biomed NV Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.42 Mil.

Mainz Biomed NV Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MYNZ:USA

Address

Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV Headlines

No Headlines